Cutaneous melanoma is a skin cancer with increasing incidence. Identification of novel clinical biomarkers able to detect the stage of disease and suggest prognosis could improve treatment and outcome for melanoma patients. Cell‐free microRNAs (cf‐miRNAs) are the circulating copies of short non‐coding RNAs involved in gene expression regulation. They are released into the interstitial fluid, are detectable in blood and other body fluids and have interesting features of ideal biomarker candi‐ dates. They are stable outside the cell, tissue specific, vary along with cancer devel‐ opment and are sensitive to change in the disease course such as progression or therapeutic response. Moreover, they are accessible by non‐invasive methods or venipuncture. Some articles have reported different cf‐miRNAs with the potential of diagnostic tools for melanoma staging, recurrence and survival prediction. Although some concordance of results is already emerging, differences in analytical methods, normalization strategies and tumour staging still will require further research and standardization prior to clinical usage of cf‐miRNA analysis. This article reviews this literature with the aim of contributing to a shared focusing on these new promising tools for melanoma treatment and care.

Circulating cell-free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis

Polini, Beatrice
Co-primo
Writing – Original Draft Preparation
;
Carpi, Sara
Co-primo
Writing – Original Draft Preparation
;
Breschi, Maria Cristina;Nieri, Paola
Penultimo
Writing – Original Draft Preparation
;
Podestà adriano
Ultimo
2019-01-01

Abstract

Cutaneous melanoma is a skin cancer with increasing incidence. Identification of novel clinical biomarkers able to detect the stage of disease and suggest prognosis could improve treatment and outcome for melanoma patients. Cell‐free microRNAs (cf‐miRNAs) are the circulating copies of short non‐coding RNAs involved in gene expression regulation. They are released into the interstitial fluid, are detectable in blood and other body fluids and have interesting features of ideal biomarker candi‐ dates. They are stable outside the cell, tissue specific, vary along with cancer devel‐ opment and are sensitive to change in the disease course such as progression or therapeutic response. Moreover, they are accessible by non‐invasive methods or venipuncture. Some articles have reported different cf‐miRNAs with the potential of diagnostic tools for melanoma staging, recurrence and survival prediction. Although some concordance of results is already emerging, differences in analytical methods, normalization strategies and tumour staging still will require further research and standardization prior to clinical usage of cf‐miRNA analysis. This article reviews this literature with the aim of contributing to a shared focusing on these new promising tools for melanoma treatment and care.
2019
Polini, Beatrice; Carpi, Sara; Romanini, Antonella; Breschi, Maria Cristina; Nieri, Paola; Podestà, Adriano
File in questo prodotto:
File Dimensione Formato  
Post_Print_Polini_Pigment_Cell_&_Melanoma_Research.pdf

Open Access dal 02/01/2020

Tipologia: Documento in Post-print
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 600.07 kB
Formato Adobe PDF
600.07 kB Adobe PDF Visualizza/Apri
2019_Polini_Podestà_Pigment_Cell_&_Melanoma_Research.pdf

solo utenti autorizzati

Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/945740
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 16
social impact